NBE-Therapeutics

Founded in 2012 and headquartered in Basel, Switzerland, NBE-Therapeutics AG specializes in innovative oncology treatments.00 mn, finalized on December 10, 2020.NBE Therapeutics specializes in the development of next-generation antibody-drug conjugates (ADCs) aimed at treating solid tumors in oncology. Their core offerings revolve around a proprietary platform that integrates novel technologies to create targeted therapies designed to enhance the efficacy of cancer treatment while minimizing side effects. The company’s ADCs leverage long-lasting immune oncology effects which could potentially reduce or eradicate tumors, thereby improving survival rates and quality of life for cancer patients. These innovative products are primarily aimed at healthcare institutions, oncologists, and research organizations across North America and Europe, where they serve an extensive client base committed to advancing cancer care.NBE Therapeutics generates revenue through strategic partnerships and collaborations with pharmaceutical companies, research institutions, and healthcare providers. The company’s revenue structure includes B2B transactions where they supply their ADC product candidates to partners engaged in clinical trials and subsequent commercialization efforts. Each partnership may involve milestone payments and royalties based on the sales performance of developed therapies.With the recent acquisition by Boehringer Ingelheim International GmbH, NBE-Therapeutics AG is positioned for significant growth.00 mn from the latest TRADE SALE to expand its product pipeline and enter new markets. Specific targets for future product launches are expected in the upcoming years, focusing on enhancing ADC therapies and expanding into Asian markets, particularly in Japan and China, by 2023.

1. Series C

   Jan 10, 2020

   Amount

   $22M

   Investors

   Locked

2. Series B

   Jun 28, 2018

   Amount

   $20M

   Investors

   Locked

3. Series B

   Nov 3, 2016

   Amount

   $21M

   Investors

   Locked

4. Series A

   Feb 20, 2015

   Amount

   $3.2M

   Investors

   Locked

5. Seed

   Dec 13, 2013

   Amount

   $2.4M

   Investors

   Locked

6. Seed

   Jan 31, 2013

   Amount

   Undisclosed

   Investors

   Locked